
    
      This is a Phase III, double-blind, randomised study assessing the efficacy and safety of
      Alflutinib Mesylate (AST2818) (80 mg orally, once daily) versus Gefitinib (250 mg orally,
      once daily] in patients with locally advanced or metastatic Non-small Cell Lung Cancer
      (NSCLC) that is known to be EGFR sensitising mutation (EGFRm) positive for first-line
      treatment with an EGFR-TKI.
    
  